Fidson Healthcare PLC H1-22 Performance Review

Currently, the local drugs manufacturers are faced with an intense competition from imported products and multinational companies. For instance, 70% of the drugs consumed in Nigeria are imported. Also, almost all the local manufacturers source their active pharmaceuticals ingredients or raw material through importation. The preceding suggests that they are merely purchasing drugs and repackaging them for use. These account for the major challenge in the pharmaceutical industry in Nigeria. Though, Fidson is currently working to expand into Active pharmaceutical production (API). Other constraints, will be infrastructural challenges such as inconsistent energy, weak technology, scarcity of forex and high taxation etc.

Financial Highlights of SEPLAT in the first 9 months of 2020

Although revenue declined, we note that the cost of sales surged during the period. Specifically, cost of sales was N103.94 billion compared to N70.65 billion recorded in the corresponding period of 2019. This was due to 95% increase in operational and maintenance expenses (N23.56 billion) and 59.4% increase in depletion, depreciation and amortisation (N33.75 billion).

Financial Highlights of Bua Cement Plc in 9M-2020

Gross profit grew by 13.6% compared to the corresponding period of 2019. The gross profit growth is however slow due to the fact that the growth in cost of sales was more than the growth in revenue. While revenue grew by 13.6% y/y, the cost of sales grew by 28.8%. Hence, gross profit printed N71.73 billion.

Scroll to top